COEP insider transaction filings

Coeptis Therapeutics Holdings, Inc. — 18 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-02-13. Screen COEP transaction legs live →

FiledFormInsiderReported transactionsSource
2026-02-134Cogley Brian — Chief Financial OfficerOption exercise (M): 10,000 @ $10.56 · Grant/award (A): 12,500 @ $0EDGAR
2026-02-134Calise Chris — DirectorOption exercise (M): 5,700 @ $10.56 · Grant/award (A): 3,250 @ $0EDGAR
2026-02-134Mehalick David — CEO and President, Director, 10% ownerOption exercise (M): 148,875 @ $7.05 · Grant/award (A): 51,250 @ $0EDGAR
2026-02-134Yerace Daniel Alexander — VP Operations, DirectorOption exercise (M): 10,000 @ $10.41 · Grant/award (A): 20,000 @ $0EDGAR
2026-02-134DeSilva Tara — DirectorOption exercise (M): 5,700 @ $10.56 · Grant/award (A): 3,250 @ $0EDGAR
2026-02-134Cochran Christopher P. — DirectorOption exercise (M): 5,700 @ $10.56 · Grant/award (A): 3,250 @ $0EDGAR
2026-02-134Sheehy Christine Elise — VP Compliance and SecyOption exercise (M): 1,000 @ $10.56 · Grant/award (A): 12,500 @ $0EDGAR
2026-02-134Deschamps Philippe — DirectorOption exercise (M): 5,700 @ $10.56 · Grant/award (A): 3,250 @ $0EDGAR
2026-02-134Salkind Gene — DirectorOption exercise (M): 5,700 @ $10.56 · Grant/award (A): 3,250 @ $0EDGAR
2025-03-104Deschamps Philippe — DirectorGrant/award (A): 5,700 (derivative)EDGAR
2025-03-064Cogley Brian — Chief Financial OfficerGrant/award (A): 10,000 (derivative)EDGAR
2025-03-064Yerace Daniel Alexander — VP of Operations, DirectorGrant/award (A): 5,000 (derivative)EDGAR
2025-03-064Sheehy Christine Elise — VP Compliance and SecyGrant/award (A): 1,000 (derivative)EDGAR
2025-03-064Mehalick David — CEO and President, Director, 10% ownerGrant/award (A): 28,875 (derivative)EDGAR
2025-03-064DeSilva Tara — DirectorGrant/award (A): 5,700 (derivative)EDGAR
2025-03-064Cochran Christopher P. — DirectorGrant/award (A): 5,700 (derivative)EDGAR
2025-03-064Calise Chris — DirectorGrant/award (A): 5,700 (derivative)EDGAR
2025-03-064Salkind Gene — DirectorGrant/award (A): 5,700 (derivative)EDGAR

Recent 8-K events — Coeptis Therapeutics Holdings, Inc.

FiledFormItems reportedSource
2026-08-048-K1.01 — Entry into a Material Definitive Agreement
1.02 — Termination of a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-228-K1.02 — Termination of a Material Definitive Agreement
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-108-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-078-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-308-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-298-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-268-K1.01 — Entry into a Material Definitive Agreement
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-048-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-018-K/A9.01 — Financial Statements and ExhibitsEDGAR
2026-05-228-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=COEP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →